Skip to Content

Skyrizi FDA Approval History

FDA Approved: Yes (First approved April 23, 2019)
Brand name: Skyrizi
Generic name: risankizumab-rzaa
Dosage form: Injection
Company: AbbVie Inc.
Treatment for: Plaque Psoriasis

Skyrizi (risankizumab-rzaa) is an interleukin-23 (IL-23) inhibitor for the treatment of plaque psoriasis.

Development Timeline for Skyrizi

DateArticle
Apr 23, 2019ApprovalFDA Approves Skyrizi (risankizumab-rzaa) for Moderate to Severe Plaque Psoriasis
Sep 13, 2018AbbVie Announces Patient-Reported Outcomes Data from Three Pivotal Phase 3 Studies of Risankizumab, Showing Significant Improvements in Health-Related Quality of Life for Patients with Psoriasis
Apr 25, 2018AbbVie Submits Biologics License Application to U.S. FDA for Investigational Treatment Risankizumab for Moderate to Severe Plaque Psoriasis

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.